Abstract
Adjusted-dose warfarin and antiplatelet agents reduce stroke by approximately 60% and by approximately 20%, respectively, in patients who have atrial fibrillation. Warfarin is substantially more efficacious (by approximately 40%) than antiplatelet therapy. Absolute increases in major extracranial hemorrhage associated with antithrombotic therapy in participants from the trials included in this meta-analysis were less than the absolute reductions in stroke. Judicious use of antithrombotic therapy importantly reduces stroke for most patients who have atrial fibrillation.
Keywords
Affiliated Institutions
Related Publications
Antithrombotic Therapy To Prevent Stroke in Patients with Atrial Fibrillation
Adjusted-dose warfarin and aspirin reduce stroke in patients with atrial fibrillation, and warfarin is substantially more efficacious than aspirin. The benefit of antithrombotic...
Oral Antithrombotic Agents for the Prevention of Stroke in Nonvalvular Atrial Fibrillation
T he rate of stroke among adults with atrial fibrilla- tion (AF) varies widely, ranging between 1% and 20% annually (mean 4.5% per year) depending on comorbidities and a patient...
Prevalence, Age Distribution, and Gender of Patients With Atrial Fibrillation
The prevalence of atrial fibrillation (AF) is related to age. Anticoagulation is highly effective in preventing stroke in patients with AF, but the risk of hemorrhage may be inc...
Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation
In patients with atrial fibrillation, rivaroxaban was noninferior to warfarin for the prevention of stroke or systemic embolism. There was no significant between-group differenc...
Publication Info
- Year
- 2007
- Type
- review
- Volume
- 146
- Issue
- 12
- Pages
- 857-867
- Citations
- 4729
- Access
- Closed
External Links
Social Impact
Social media, news, blog, policy document mentions
Citation Metrics
Cite This
Identifiers
- DOI
- 10.7326/0003-4819-146-12-200706190-00007